Literature DB >> 10102436

Single-day praziquantel versus 1-week albendazole for neurocysticercosis.

O H Del Brutto1, X Campos, J Sánchez, A Mosquera.   

Abstract

The efficacy of albendazole (15 mg/kg/d for 1 week) was compared with praziquantel (100 mg/kg in three divided doses at 2-hour intervals) for therapy of parenchymal brain cysticercosis. Ten patients were treated with albendazole and 10 patients with praziquantel. Although the total number of cysts was significantly reduced from 64 to 7 in patients treated with albendazole and from 59 to 24 in those treated with praziquantel, the number of patients improving with albendazole was not significantly different from those treated with praziquantel.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10102436     DOI: 10.1212/wnl.52.5.1079

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  13 in total

1.  Neurocysticercosis.

Authors:  Oscar H Del Brutto
Journal:  Neurohospitalist       Date:  2014-10

2.  Cysticercosis.

Authors:  J F Bale
Journal:  Curr Treat Options Neurol       Date:  2000-07       Impact factor: 3.598

Review 3.  Neurocysticercosis--New Millennium, ancient disease and unending debate.

Authors:  G Narula; K S Bawa
Journal:  Indian J Pediatr       Date:  2003-04       Impact factor: 1.967

Review 4.  Hydrocephalus in neurocysticercosis.

Authors:  Hamilton Matushita; Fernando Campos Gomes Pinto; Daniel Dante Cardeal; Manoel Jacobsen Teixeira
Journal:  Childs Nerv Syst       Date:  2011-09-17       Impact factor: 1.475

Review 5.  Anthelmintics for people with neurocysticercosis.

Authors:  Katharine Abba; Sridharan Ramaratnam; Lakshmi Narasimhan Ranganathan
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

Review 6.  Neurocysticercosis: a review on status in India, management, and current therapeutic interventions.

Authors:  Rumana Ahmad; Tahmeena Khan; Bilal Ahmad; Aparna Misra; Anil K Balapure
Journal:  Parasitol Res       Date:  2016-10-24       Impact factor: 2.289

Review 7.  Proposed diagnostic criteria for neurocysticercosis.

Authors:  O H Del Brutto; V Rajshekhar; A C White; V C Tsang; T E Nash; O M Takayanagui; P M Schantz; C A Evans; A Flisser; D Correa; D Botero; J C Allan; E Sarti; A E Gonzalez; R H Gilman; H H García
Journal:  Neurology       Date:  2001-07-24       Impact factor: 9.910

Review 8.  Management of neurocysticercosis.

Authors:  Terrence Riley; A C White
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 9.  Current consensus guidelines for treatment of neurocysticercosis.

Authors:  Hector H García; Carlton A W Evans; Theodore E Nash; Osvaldo M Takayanagui; A Clinton White; David Botero; Vedantam Rajshekhar; Victor C W Tsang; Peter M Schantz; James C Allan; Ana Flisser; Dolores Correa; Elsa Sarti; Jon S Friedland; S Manuel Martinez; Armando E Gonzalez; Robert H Gilman; Oscar H Del Brutto
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

10.  Recent Developments in the Epidemiology, Diagnosis, Treatment, and Prevention of Neurocysticercosis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-12       Impact factor: 3.663

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.